BIOMAT Database Logo BIOMAT Database Logo

Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. 2002

Paul Krogstad, and Sophia Lee, and George Johnson, and Kenneth Stanley, and James McNamara, and John Moye, and J Brooks Jackson, and Rosaura Aguayo, and Arry Dieudonne, and Margaret Khoury, and Hermann Mendez, and Sharon Nachman, and Andrew Wiznia, and
University of California, Los Angeles School of Medicine, Departments of Pediatrics and Molecular and Medical Pharmacology, Los Angeles, CA, 90095, USA. pkrogstad@mednet.ucla.edu

The relative potency and tolerability of multidrug regimens used to treat infants and children infected with human immunodeficiency virus type 1 (HIV-1) are largely unknown. In Pediatric AIDS Clinical Trials Group (PACTG) Protocol 377, 181 infants and children were assigned to receive stavudine (d4T) plus nevirapine (NVP) and ritonavir (RTV); d4T plus lamivudine (3TC) and nelfinavir (NFV); d4T plus NVP and NFV; or d4T plus 3TC, NVP, and NFV. Eleven additional children received d4T and NVP plus NFV given twice daily. All subjects had not previously received protease inhibitors or nonnucleoside reverse-transcriptase inhibitors and all had been immunologically stable while receiving reverse-transcriptase inhibitor therapy. After 48 weeks of therapy, 17 (41%) of 41 subjects receiving d4T-NVP-RTV, 13 (30%) of 44 receiving d4T-NVP-NFV, 21 (42%) of 50 receiving d4T-3TC and NFV (3 times daily), and 22 (52%) of 42 receiving d4T-3TC-NVP-NFV were still receiving their assigned therapy and had HIV-1 RNA suppression to </= 400 copies/mL. These regimens were similar in their drug activity, but the 4-drug regimen offered slightly more durable suppression of viremia.

UI MeSH Term Description Entries
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

Paul Krogstad, and Sophia Lee, and George Johnson, and Kenneth Stanley, and James McNamara, and John Moye, and J Brooks Jackson, and Rosaura Aguayo, and Arry Dieudonne, and Margaret Khoury, and Hermann Mendez, and Sharon Nachman, and Andrew Wiznia, and
Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
January 2004, Current topics in medicinal chemistry,
Paul Krogstad, and Sophia Lee, and George Johnson, and Kenneth Stanley, and James McNamara, and John Moye, and J Brooks Jackson, and Rosaura Aguayo, and Arry Dieudonne, and Margaret Khoury, and Hermann Mendez, and Sharon Nachman, and Andrew Wiznia, and
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
March 2002, The Journal of infectious diseases,
Paul Krogstad, and Sophia Lee, and George Johnson, and Kenneth Stanley, and James McNamara, and John Moye, and J Brooks Jackson, and Rosaura Aguayo, and Arry Dieudonne, and Margaret Khoury, and Hermann Mendez, and Sharon Nachman, and Andrew Wiznia, and
Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
December 1999, The New England journal of medicine,
Paul Krogstad, and Sophia Lee, and George Johnson, and Kenneth Stanley, and James McNamara, and John Moye, and J Brooks Jackson, and Rosaura Aguayo, and Arry Dieudonne, and Margaret Khoury, and Hermann Mendez, and Sharon Nachman, and Andrew Wiznia, and
Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1.
March 1995, The Journal of infectious diseases,
Paul Krogstad, and Sophia Lee, and George Johnson, and Kenneth Stanley, and James McNamara, and John Moye, and J Brooks Jackson, and Rosaura Aguayo, and Arry Dieudonne, and Margaret Khoury, and Hermann Mendez, and Sharon Nachman, and Andrew Wiznia, and
ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase.
July 2002, Antimicrobial agents and chemotherapy,
Paul Krogstad, and Sophia Lee, and George Johnson, and Kenneth Stanley, and James McNamara, and John Moye, and J Brooks Jackson, and Rosaura Aguayo, and Arry Dieudonne, and Margaret Khoury, and Hermann Mendez, and Sharon Nachman, and Andrew Wiznia, and
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.
January 2003, Antimicrobial agents and chemotherapy,
Paul Krogstad, and Sophia Lee, and George Johnson, and Kenneth Stanley, and James McNamara, and John Moye, and J Brooks Jackson, and Rosaura Aguayo, and Arry Dieudonne, and Margaret Khoury, and Hermann Mendez, and Sharon Nachman, and Andrew Wiznia, and
Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors.
March 2003, American journal of human genetics,
Paul Krogstad, and Sophia Lee, and George Johnson, and Kenneth Stanley, and James McNamara, and John Moye, and J Brooks Jackson, and Rosaura Aguayo, and Arry Dieudonne, and Margaret Khoury, and Hermann Mendez, and Sharon Nachman, and Andrew Wiznia, and
Anti-human immunodeficiency virus type 1 activities of novel non-nucleoside reverse transcriptase inhibitors.
February 1994, The Journal of antimicrobial chemotherapy,
Paul Krogstad, and Sophia Lee, and George Johnson, and Kenneth Stanley, and James McNamara, and John Moye, and J Brooks Jackson, and Rosaura Aguayo, and Arry Dieudonne, and Margaret Khoury, and Hermann Mendez, and Sharon Nachman, and Andrew Wiznia, and
Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 5. 4-Substituted and 2,4-disubstituted analogs of nevirapine.
November 1995, Journal of medicinal chemistry,
Paul Krogstad, and Sophia Lee, and George Johnson, and Kenneth Stanley, and James McNamara, and John Moye, and J Brooks Jackson, and Rosaura Aguayo, and Arry Dieudonne, and Margaret Khoury, and Hermann Mendez, and Sharon Nachman, and Andrew Wiznia, and
Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.
December 2007, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!